Omega-3 polyunsaturated fatty acids/turmeric Drug Interactions
Currently displaying a list of 141 drugs known to interact with omega-3 polyunsaturated fatty acids / turmeric.
- 141 moderate drug interactions
Medications known to interact with omega-3 polyunsaturated fatty acids/turmeric
Note: Showing generic names only.
A
- abciximab
- acarbose
- acetohexamide
- albiglutide
- alogliptin
- alteplase
- anagrelide
- anisindione
- anistreplase
- antithrombin (recombinant)
- antithrombin iii
- apixaban
- ardeparin
- argatroban
- aspirin
B
C
- canagliflozin
- cangrelor
- caplacizumab
- celecoxib
- chlorpropamide
- cilostazol
- citalopram
- clomipramine
- clopidogrel
D
- dabigatran
- dalteparin
- danaparoid
- dapagliflozin
- defibrotide
- desirudin
- desvenlafaxine
- dextran 1
- dextran, high molecular weight
- dextran, low molecular weight
- diclofenac
- dicumarol
- diflunisal
- dipyridamole
- drotrecogin alfa
- dulaglutide
- duloxetine
E
- edoxaban
- empagliflozin
- enoxaparin
- epoprostenol
- eptifibatide
- ertugliflozin
- escitalopram
- etodolac
- exenatide
F
G
H
I
- ibuprofen
- iloprost
- indomethacin
- inotersen
- insulin
- insulin aspart
- insulin aspart protamine
- insulin degludec
- insulin detemir
- insulin glargine
- insulin glulisine
- insulin inhalation, rapid acting
- insulin isophane
- insulin lispro
- insulin lispro protamine
- insulin regular
- insulin zinc
- insulin zinc extended
K
L
M
N
O
P
R
S
- saxagliptin
- semaglutide
- sertraline
- sibutramine
- sitagliptin
- sotagliflozin
- streptokinase
- sulfasalazine
- sulfinpyrazone
- sulindac
T
- talazoparib
- tenecteplase
- ticagrelor
- ticlopidine
- tinzaparin
- tirofiban
- tirzepatide
- tolazamide
- tolbutamide
- tolmetin
- treprostinil
- troglitazone
U
V
W
Omega-3 polyunsaturated fatty acids/turmeric disease interactions
There are 2 disease interactions with omega-3 polyunsaturated fatty acids / turmeric which include:
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.